Therapeutic response across several models and acute effects in the tumor microenvironment. (A) Tumor growth inhibition following treatment with 1V270-micelles, anti-PD1 and the combination across 12 syngeneic mouse cancer models. Treatment started when tumors reached ∼100 mm³. Treatments with 16.5 mg/kg 1V270-micelles were given every fourth day (q4d) for a total of 5 treatments. The 10 mg/kg anti-PD1 was given every fourth day for a total of 6 treatments. For combination treatment, anti-PD1 treatment started two days later than 1V270-micelle treatment. Tumor growth inhibition (TGI) is shown for the indicated treatment groups (n = 6–10). Underlining tumor growth curves is shown in Fig. S16. (B–D): Mice bearing different tumor models (indicated by color) were treated with 11 mg/kg 1V270-micelles, and tumors evaluated 6 and 24 h after treatment (indicated by shading) by flow cytometry (n = 3–8). CT26 tumor data from Fig. 2C–E was reused for the sake of comparison to other models. (B) Overall cellular viability in tumors. (C) Erythrocyte content in tumors. (D) Neutrophil infiltration into tumors. Gating for B–C is shown in Fig. S8. Gating for D is shown in Fig. S10. Statistical analyses were a 2-way ANOVA with Tukey's multiple comparisons tests (A) and Dunnett’s multiple comparisons tests (B–D).